Neofact® - Medical device for surfactant application

Lyomark Pharma Ltd offers a wide range of services which includes manufacturing services. It has been working for many years with reliable and internationally operating contract manufacturers. Each product is constantly accompanied by the development, on the approval and production to ready-made sales of goods. It regularly audited its suppliers to ensure the consistently high quality of products. Through years of market knowledge and expertise of employees in the field of contract manufacturing to get customized services for product and your market. It includes a pharmaceutical formulation development service; development from pilot scale to validated commercial batch size. Contact us for more information.

Lyomark Pharma Ltd offers a wide range of services which includes active ingredients service. It collaborates with leading pharmaceutical manufacturers from around the world in the development and marketing of pharmaceutical raw materials and active ingredients. It helps to market analysis and choosing the right supplier and provides access to a comprehensive range of active pharmaceutical ingredients including the necessary documentation, such as cep and edmf.. Contact us for more information.

Lyomark Pharma Ltd offers a wide range of services which includes regulatory services. It offers different regulatory services to clients from the pharmaceutical industry. In addition to the provision of our products and the dossiers based on submission of approvals and following further services are available such as product quality review (pqr)-the creation of the pqr, the intervals respectively desired if necessary, to. Alternatively, the raw data for their own creation of the pqr be provided. Database query-performs at desired intervals through regular polling of relevant databases. Periodic safety update report (psur)- the psur to the respective desired intervals and prepare it on submission requirements. If desired, also internal company data are implemented.. Contact us for more information.

Lyomark Pharma Ltd offers a wide range of services which includes distribution services. It distributes since 2007 its own products directly in the german hospital market. In addition to direct sales in germany will award it also has distribution licenses to international distribution partner for the worldwide distribution of pharmaceutical products. Contact us for more information.

Alveofact is used in neonates. Preventive use in premature neonates with a high risk of respiratory distress syndrome (RDS).
Active substance: Phospholipid fractionfrom bovine lung (surfactant)

Vancomycin Lyomark 500 mg and 1000mgPowder for concentrate for solution for infusion or oral solution.

Somatostatin 3mg

Powder for solution for infusion

NeoKay® is a medicinal product used for the prophylaxis of vitamin K1 deficiency bleeding in healthy infants from the 36th week of gestation.
Each soft capsule contains 1 mg phytomenadione (vitamin K1).

Pack sizes of 12s (retail) and 100s (hospital) are available.


Shelf life:3 years
After opening: 12 weeks

Octreotid Bendalis 0.05 mg/ml
Octreotid Bendalis 0.1 mg/ml
Octreotid Bendalis 0.5 mg/ml
Octreotid Bendalis 0.2 mg/ml

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive surfactant administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing.An extremely high success rate could be achieved (95%).


https://pubmed.ncbi.nlm.nih.gov/33023914/

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and can also be used at any gestational age.

https://pubmed.ncbi.nlm.nih.gov/33023914/

In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/

Lyomark Pharma: NeoKay® - a vitamin-K1-prophylaxis for the German market.

 Avoidance of plastic waste - New packaging for Alveofact®